MENU
MRUS
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Merus (MRUS) Ownership - Who owns Merus?
Merus NV is a clinical-stage immuno-oncology company... Show more
Industry: #Biotechnology
Profile
Industry
Biotechnology
Address
Uppsalalaan 17
Phone
+31 302538800
Employees
229
Web
https://www.merus.nl
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
4.97B
P/E Ratio
N/A
Total Cash
710.22M
Projected Growth
N/A
Total Debt
11M
Revenue
56.23M
Risk (Beta)
1.05
Dividend Yield
N/A
Total Cash/Share
9.39
Total Debt/Equity
N/A
Revenue/Share
0.81 USD as % of share price
Fundamentals
MRUS
Capitalization
4.97B
P/E Ratio
N/A
Risk (Beta)
1.05
Dividend Yield
N/A
Total Cash
710M
Total Cash/Share
9.39
Total Debt
11M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.81%
Revenue
56.2M
ROE
N/A
Book Value
842M
P/B Ratio
5.91
Cash Flow
N/A
Earnings
-5.58
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
7.65M
Current Ratio
8.39
Current Revenue Per Employee
33953.85
Dividends Per Share - Security
N/A
EBITDA
-347.56M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-41.18
Shares Held By Institutions
5.22B
Shares Outstanding - Current
75.6M
Total Liabilities
138M
Total Volume MTD
N/A
Value
N/A
Gain YTD
56.338
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. MRUS showed earnings on August 05, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information
General Information
a developer of therapeutics for cancer treatment
Industry Biotechnology
Profile
Fundamentals
Details
Industry
Biotechnology
Address
Uppsalalaan 17
Phone
+31 302538800
Employees
229
Web
https://www.merus.nl